David A Degoey

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1156186/publications.pdf

Version: 2024-02-01

		1163117	1372567	
10	638	8	10	
papers	citations	h-index	g-index	
11	11	11	993	
all docs	docs citations	times ranked	citing authors	

#	Article	IF	CITATIONS
1	Beyond the Rule of 5: Lessons Learned from AbbVie's Drugs and Compound Collection. Journal of Medicinal Chemistry, 2018, 61, 2636-2651.	6.4	261
2	<i>In Vitro</i> and <i>In Vivo</i> Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A. Antimicrobial Agents and Chemotherapy, 2015, 59, 979-987.	3.2	128
3	Discovery of ABT-267, a Pan-Genotypic Inhibitor of HCV NS5A. Journal of Medicinal Chemistry, 2014, 57, 2047-2057.	6.4	120
4	Discovery of pyrido [2,3-d] pyrimidine-based inhibitors of HCV NS5A. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 3627-3630.	2.2	43
5	Water-Soluble Prodrugs of the Human Immunodeficiency Virus Protease Inhibitors Lopinavir and Ritonavir. Journal of Medicinal Chemistry, 2009, 52, 2964-2970.	6.4	31
6	Implications of the Conformationally Flexible, Macrocyclic Structure of the First-Generation, Direct-Acting Anti-Viral Paritaprevir on Its Solid Form Complexity and Chameleonic Behavior. Journal of the American Chemical Society, 2021, 143, 17479-17491.	13.7	27
7	Global Analysis of Models for Predicting Human Absorption: QSAR, <i>In Vitro</i> , and Preclinical Models. Journal of Medicinal Chemistry, 2021, 64, 9389-9403.	6.4	13
8	Prodrug Strategies to Improve the Solubility of the HCV NS5A Inhibitor Pibrentasvir (ABT-530). Journal of Medicinal Chemistry, 2020, 63, 11034-11044.	6.4	9
9	Desymmetrization of pibrentasvir for efficient prodrug synthesis. Chemical Science, 2021, 12, 10076-10082.	7.4	5
10	HCV NS5A as an Antiviral Therapeutic Target: From Validation to the Discovery and Development of Ombitasvir and Pibrentasvir as Components of IFN-Sparing HCV Curative Treatments. Topics in Medicinal Chemistry, 2019, , 133-156.	0.8	1